Boston Trust Walden Corp Purchases 202,609 Shares of Haemonetics Corporation (NYSE:HAE)

Boston Trust Walden Corp raised its stake in Haemonetics Corporation (NYSE:HAE - Free Report) by 22.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,118,331 shares of the medical instruments supplier's stock after acquiring an additional 202,609 shares during the period. Boston Trust Walden Corp owned approximately 2.23% of Haemonetics worth $71,070,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Thrivent Financial for Lutherans raised its holdings in Haemonetics by 14.9% in the 4th quarter. Thrivent Financial for Lutherans now owns 1,264,294 shares of the medical instruments supplier's stock valued at $98,716,000 after acquiring an additional 164,111 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Haemonetics by 1.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 992,229 shares of the medical instruments supplier's stock valued at $77,470,000 after acquiring an additional 10,990 shares in the last quarter. Fisher Asset Management LLC raised its holdings in Haemonetics by 3.2% in the 4th quarter. Fisher Asset Management LLC now owns 711,774 shares of the medical instruments supplier's stock valued at $55,575,000 after acquiring an additional 22,265 shares in the last quarter. Northern Trust Corp raised its holdings in Haemonetics by 16.1% in the 4th quarter. Northern Trust Corp now owns 678,261 shares of the medical instruments supplier's stock valued at $52,959,000 after acquiring an additional 93,848 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC raised its holdings in Haemonetics by 31.0% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 643,227 shares of the medical instruments supplier's stock valued at $50,223,000 after acquiring an additional 152,042 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HAE has been the subject of several analyst reports. JMP Securities reaffirmed a "market outperform" rating and issued a $100.00 price objective on shares of Haemonetics in a report on Tuesday, May 20th. Raymond James Financial reaffirmed a "strong-buy" rating and issued a $105.00 price objective (down from $115.00) on shares of Haemonetics in a report on Friday, May 9th. Needham & Company LLC decreased their price target on Haemonetics from $104.00 to $84.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Finally, Wall Street Zen lowered Haemonetics from a "buy" rating to a "hold" rating in a research note on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $97.89.

Haemonetics Price Performance

Shares of HAE traded up $1.14 during midday trading on Friday, hitting $71.20. The company's stock had a trading volume of 662,869 shares, compared to its average volume of 679,766. Haemonetics Corporation has a one year low of $55.30 and a one year high of $94.99. The company's fifty day simple moving average is $66.23 and its two-hundred day simple moving average is $68.48. The company has a quick ratio of 0.99, a current ratio of 1.62 and a debt-to-equity ratio of 1.12. The stock has a market capitalization of $3.42 billion, a price-to-earnings ratio of 21.51, a price-to-earnings-growth ratio of 1.15 and a beta of 0.36.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.02. The company had revenue of $330.60 million for the quarter, compared to analyst estimates of $329.38 million. Haemonetics had a return on equity of 26.37% and a net margin of 12.32%. The company's revenue for the quarter was down 3.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.90 EPS. As a group, equities analysts expect that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.